As the authors note, it is important to list and discuss some limitations of this research, as well as those of other, similar studies. Despite over 14 years of research, diffusion tensor imaging is still in its infancy when it comes to clinical applications. In general, two of the major limitations of clinical research with this technology, which have hampered progress in the field, are 1) variability in acquisition and analytic techniques and 2) lack of validation of the methodology, including derived white matter measures. While the former is probably responsible for most of the inconsistencies in the literature on diffusion tensor imaging studies of schizophrenia, the latter is even more significant. More specifically, despite over 80 studies that have been published to date that used diffusion tensor imaging in schizophrenia research, it is still not known whether when we report group differences in fractional anisotropy, or any other popular or less popular diffusion index, what we report are abnormalities in myelination, axonal integrity, variability in tract orientation and organization, all of these, or none of these. It is still also not known how different parameters of image acquisition, processing, and analysis impact results and whether results indicate real white matter abnormalities or are merely indicative of biases introduced by specific image analysis approaches (in the case of voxel-based morphometry, used in this study, errors in automatic normalization, segmentation, and registration). It is further not known how age, medication, eating and drinking habits, etc., influence the diffusion tensor imaging signal.